Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $34.81 in the prior trading day, Ionis Pharmaceuticals Inc (NASDAQ: IONS) closed at $34.10, down -2.04%. In other words, the price has decreased by -$2.04 from its previous closing price. On the day, 1.14 million shares were traded. IONS stock price reached its highest trading level at $35.15 during the session, while it also had its lowest trading level at $33.92.
Ratios:
Our goal is to gain a better understanding of IONS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.82 and its Current Ratio is at 8.91. In the meantime, Its Debt-to-Equity ratio is 3.00 whereas as Long-Term Debt/Eq ratio is at 2.93.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BMO Capital Markets on August 02, 2024, Downgraded its rating to Market Perform and sets its target price to $60 from $67 previously.
On July 24, 2024, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform and also upped its target price recommendation from $53 to $62.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 23 ’24 when Hayden Michael R bought 5,000 shares for $36.22 per share. The transaction valued at 181,079 led to the insider holds 35,219 shares of the business.
Swayze Eric sold 1,194 shares of IONS for $45,278 on Nov 12 ’24. The EVP Research now owns 33,713 shares after completing the transaction at $37.92 per share. On Nov 12 ’24, another insider, Monia Brett P, who serves as the Chief Executive Officer of the company, sold 6,630 shares for $38.05 each. As a result, the insider received 252,294 and left with 167,393 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IONS now has a Market Capitalization of 5496408064 and an Enterprise Value of 4888112640. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.72 while its Price-to-Book (P/B) ratio in mrq is 8.12. Its current Enterprise Value per Revenue stands at 6.087 whereas that against EBITDA is -14.536.
Stock Price History:
The Beta on a monthly basis for IONS is 0.35, which has changed by -0.34171712 over the last 52 weeks, in comparison to a change of 0.24933672 over the same period for the S&P500. Over the past 52 weeks, IONS has reached a high of $54.44, while it has fallen to a 52-week low of $33.33. The 50-Day Moving Average of the stock is -7.42%, while the 200-Day Moving Average is calculated to be -18.02%.
Shares Statistics:
The stock has traded on average 1.40M shares per day over the past 3-months and 1523020 shares per day over the last 10 days, according to various share statistics. A total of 157.81M shares are outstanding, with a floating share count of 145.55M. Insiders hold about 7.82% of the company’s shares, while institutions hold 98.07% stake in the company. Shares short for IONS as of 1734048000 were 10528956 with a Short Ratio of 7.50, compared to 1731628800 on 11050361. Therefore, it implies a Short% of Shares Outstanding of 10528956 and a Short% of Float of 7.7800006.
